{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:16:30Z","timestamp":1791515790257,"version":"4.3.4"},"reference-count":106,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1080\/19420862.2019.1703531","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T01:34:48Z","timestamp":1576632888000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":415,"title":["Antibodies to watch in 2020"],"prefix":"10.1080","volume":"12","author":[{"given":"H\u00e9l\u00e8ne","family":"Kaplon","sequence":"first","affiliation":[{"name":"Institut de Recherches Servier","place":["Croissy-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinalini","family":"Muralidharan","sequence":"additional","affiliation":[{"name":"The Antibody Society","place":["Framingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita","family":"Schneider","sequence":"additional","affiliation":[{"name":"Scholar Rock, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-1951","authenticated-orcid":false,"given":"Janice M.","family":"Reichert","sequence":"additional","affiliation":[{"name":"The Antibody Society","place":["Framingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,12,26]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1556465"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1415671"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1269580"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1125583"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.988944"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29282"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27333"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.24990"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22976"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.1.18719"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13895"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.1.10677"},{"key":"e_1_3_4_14_1","unstructured":"U.S. Food and Drug Administration. Drug approval package: CABLIVI. [cited 2019 Dec 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761112Orig1s000TOC.cfm"},{"key":"e_1_3_4_15_1","unstructured":"European Medicines Agency. Annex I summary of product characteristics. [cited 2019 Dec 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cablivi-epar-product-information_en.pdf."},{"key":"e_1_3_4_16_1","unstructured":"Amgen Inc. EVENITY\u2122 (romosozumab) receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture. 2019 Jan 8. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.amgen.com\/media\/news-releases\/2019\/01\/evenity-romosozumab-receives-approval-in-japan-for-the-treatment-of-osteoporosis-in-patients-at-high-risk-of-fracture\/."},{"key":"e_1_3_4_17_1","unstructured":"U.S. Food and Drug Administration. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. 2019 Apr 9. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture."},{"key":"e_1_3_4_18_1","unstructured":"UCB Amgen. EVENITY\u00ae (romosozumab) receives positive CHMP opinion for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. 2019 Oct 18. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/EVENITY-romosozumab-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Severe-Osteoporosis-in-Postmenopausal-Women-at-High-Risk-of-Fracture."},{"key":"e_1_3_4_19_1","unstructured":"U.S. Food and Drug Administration. SKYRIZI approval letter. [cited 2019 Dec 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/761105s000ltr.pdf."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"e_1_3_4_21_1","unstructured":"Langley RG Blauvelt A Gooderham M Papp K Philipp S Wu JJ Igarashi A Geng Z Wu T Camez A et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the phase 3 IMMhance trial. [cited 2019 Dec 5]. Available from: https:\/\/server.aad.org\/eposters\/Submissions\/getFile.aspx?id=10093&type=sub."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_3_4_23_1","unstructured":"U.S. Food and Drug Administration. Polivy approval letter. [cited 2019 Dec 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/761121Orig1s000ltr.pdf."},{"key":"e_1_3_4_24_1","unstructured":"Novartis. Novartis receives FDA approval for Beovu\u00ae offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. 2019 Oct 8. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_3_4_26_1","unstructured":"Novartis. Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD. 2018 Oct 27. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd."},{"key":"e_1_3_4_27_1","unstructured":"US Food and Drug Administration. FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease. 2019 Nov 15. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-treat-patients-painful-complication-sickle-cell-disease."},{"key":"e_1_3_4_28_1","unstructured":"Novartis. FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101). 2019 Jul 16. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25308"},{"key":"e_1_3_4_30_1","unstructured":"BIOCAD. BIOCAD registered the first Russian original therapeutic monoclonal antibody 2019 May 7. press release. [[cited 2019 Dec 5]. Available from: https:\/\/biocadglobal.com\/post\/Russian_original_therapeutic_monoclonal_antibody."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cryst9030177"},{"key":"e_1_3_4_32_1","unstructured":"Zydus. Zydus to launch novel biologic for rabies TwinrabTM. [cited 2019 Dec 5]. Available from: https:\/\/zyduscadila.com\/public\/pdf\/pressrelease\/Zydus%20to%20launch%20novel%20biologic%20for%20rabies_WHO.pdf."},{"key":"e_1_3_4_33_1","unstructured":"U.S. Food and Drug Administration. Monoclonal antibody product development for rabies post-exposure prophylaxis. 2017 Jul 17. https:\/\/www.fda.gov\/media\/107165\/download."},{"key":"e_1_3_4_34_1","doi-asserted-by":"crossref","unstructured":"Alder BioPharmaceuticals Inc. Alder BioPharmaceuticals reports second quarter 2019 financial and operating results. 2019 Aug 6. press release. [cited 2019 Dec 5]. Available from: https:\/\/investor.alderbio.com\/news-releases\/news-release-details\/alder-biopharmaceuticalsr-reports-second-quarter-2019-financial.","DOI":"10.1016\/j.fos.2019.03.069"},{"key":"e_1_3_4_35_1","unstructured":"Horizon Pharma plc. Horizon Pharma plc announces Phase 3 confirmatory trial evaluating teprotumumab (OPTIC) for the treatment of active thyroid eye disease (TED) met primary and all secondary endpoints. 2019 Feb 28. press release. [cited 2019 Dec 5]. Available from: https:\/\/ir.horizontherapeutics.com\/news-releases\/news-release-details\/horizon-pharma-plc-announces-phase-3-confirmatory-trial."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949"},{"key":"e_1_3_4_37_1","unstructured":"Horizon Pharma plc. Horizon therapeutics plc announces the FDA has granted priority review of the teprotumumab biologics license application (BLA) for the treatment of active thyroid eye disease (TED). 2019 Sept 9. press release. [cited 2019 Dec 5]. Available from: https:\/\/ir.horizontherapeutics.com\/news-releases\/news-release-details\/horizon-therapeutics-plc-announces-fda-has-granted-priority."},{"key":"e_1_3_4_38_1","unstructured":"Seattle Genetics Astellas. Seattle Genetics and Astellas announce submission of biologics license application to FDA for enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer. 2019 Jul 16. press release. [cited 2019 Dec 5]. Available from: http:\/\/investor.seattlegenetics.com\/news-releases\/news-release-details\/seattle-genetics-and-astellas-announce-submission-biologics."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4505"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"e_1_3_4_41_1","unstructured":"Sanofi. Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed\/refractory multiple myeloma. 2019 June 2. press release. [cited 2019 Dec 5]. Available from: http:\/\/www.news.sanofi.us\/press-releases?item=137220."},{"key":"e_1_3_4_42_1","unstructured":"Sanofi. FDA to review isatuximab as a potential treatment for relapsed\/refractory multiple myeloma. 2019 Jul 10. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2019\/2019-07-10-07-00-00."},{"key":"e_1_3_4_43_1","unstructured":"AstraZeneca and Daiichi Sankyo Company Limited. Trastuzumab deruxtecan granted FDA priority review for treatment of patients with HER2-positive metastatic breast cancer. 2019 Oct 17. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019.html."},{"key":"e_1_3_4_44_1","unstructured":"AstraZeneca and Daiichi Sankyo Company Limited. Pivotal phase II DESTINY-Breast01 trial met primary endpoint supporting global regulatory submission plan to start in H2 2019. 2019 May 8. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need-08052019.html."},{"key":"e_1_3_4_45_1","unstructured":"Daiichi Sankyo Company Limited. Daiichi Sankyo advances [Fam-] Trastuzumab deruxtecan (DS-8201) in Japan with regulatory submission in HER2 positive metastatic breast cancer. 2019 Sept 9. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.daiichisankyo.com\/media_investors\/media_relations\/press_releases\/detail\/007047.html."},{"key":"e_1_3_4_46_1","unstructured":"AstraZeneca and Daiichi Sankyo Company Limited. AstraZeneca announces two lancet oncology publications of phase I dose-expansion results of trastuzumab deruxtecan in HER2-positive metastatic breast and gastric cancer. 2019 Apr 29. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/medical-releases\/astrazeneca-announces-two-lancet-oncology-publications-of-phase-i-dose-expansion-results-of-trastuzumab-deruxtecan-in-her2-positive-metastatic-breast-and-gastric-cancer.html#!"},{"key":"e_1_3_4_47_1","unstructured":"Viela Bio. Viela Bio announces U.S. fda accepts for review inebilizumab biologics license application for neuromyelitis optica spectrum disorder. 2019 Aug 27. press release. [cited 2019 Dec 5]. Available from: https:\/\/vielabio.com\/bla_accept\/."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_4_49_1","unstructured":"CytoDyn Inc. CytoDyn reaches historical milestone submits first of three sections of BLA to FDA for Leronlimab (PRO 140) as a combination therapy for HIV. 2019 Mar 18. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.cytodyn.com\/investors\/news-events\/press-releases\/detail\/321\/cytodyn-reaches-historical-milestonesubmits-first-of."},{"key":"e_1_3_4_50_1","unstructured":"CytoDyn Inc. Investor presentation. 2019 Sept 25.https:\/\/content.equisolve.net\/_cb938b9f9372eed3b2f00594e8a2df74\/cytodyn\/db\/193\/2912\/pdf\/CytoDyn+-+Investor_presentation+-+Sep-25-2019-Final.pdf."},{"key":"e_1_3_4_51_1","unstructured":"CytoDyn Inc. CytoDyn provides update on dose escalating trial with leronlimab for HIV monotherapy for a potential pivotal trial. 2019 Aug 14. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.cytodyn.com\/newsroom\/press-releases\/detail\/350\/cytodyn-provides-update-on-dose-escalating-trial-with."},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1632115"},{"key":"e_1_3_4_53_1","unstructured":"Immunomedics Inc. Immunomedics receives complete response letter from FDA for sacituzumab govitecan biologics license application. 2019 Jan 17. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.immunomedics.com\/our-company\/news-and-events\/immunomedics-receives-complete-response-letter-from-fda-for-sacituzumab-govitecan-biologics-license-application\/."},{"key":"e_1_3_4_54_1","unstructured":"Immunomedics Inc. Immunomedics resubmits biologics license application to the FDA for sacituzumab govitecan. 2019 Dec 3. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.immunomedics.com\/our-company\/news-and-events\/immunomedics-resubmits-biologics-license-application-to-the-fda-for-sacituzumab-govitecan\/."},{"key":"e_1_3_4_55_1","unstructured":"Immunomedics Inc. Immunomedics and everest medicines announce exclusive license agreement for sacituzumab govitecan in East and Southeast Asia excluding Japan. 2019 Apr 29. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.immunomedics.com\/our-company\/news-and-events\/immunomedics-and-everest-medicines-announce-exclusive-license-agreement-for-sacituzumab-govitecan-in-east-and-southeast-asia-excluding-japan\/."},{"key":"e_1_3_4_56_1","unstructured":"European Medicines Agency. Applications for new human medicines under evaluation by the committee for medicinal products for human use. 2019 Oct. [cited 2019 Dec 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/report\/applications-new-human-medicines-under-evaluation-chmp-october-2019_en.pdf."},{"key":"e_1_3_4_57_1","unstructured":"Chugai Pharmaceutical Co. Ltd. chugai receives orphan drug designation for satralizumab in neuromyelitis optica and neuromyelitis optica spectrum disorder from the ministry of health labour and welfare. 2019 Sept 13. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20190913140000_646.html."},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_4_59_1","unstructured":"Chugai Pharmaceutical Co. Ltd. Chugai presents results from second positive global Phase III clinical study of satralizumab in NMOSD at ECTRIMS 2019. 2019 Sept 12. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20190912140300_638.html."},{"key":"e_1_3_4_60_1","unstructured":"Omeros Corporation. Narsoplimab (OMS721). Omeros corporation streamlines path to biologics license application for OMS721 in HSTC-TMA following meeting with FDA. 2019 Feb 14. press release. [cited 2019 Dec 5]. Available from: https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-streamlines-path-biologics-license."},{"key":"e_1_3_4_61_1","unstructured":"Omeros Corporation. Omeros corporation initiates BLA submission for narsoplimab for the treatment of HSCT-TMA. 2019 Oct 28. press release. [cited 2019 Dec 5]. Available from: https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-initiates-bla-submission-narsoplimab."},{"key":"e_1_3_4_62_1","first-page":"PF724","article-title":"Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathies (HCT-TMA)","volume":"215162","author":"Rambaldi A","year":"2018","unstructured":"Rambaldi A, Khaled S, Smith M, Zecca M, Kwong YM, Claes K, Leung N, Whitaker S. Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathies (HCT-TMA). Eur Hematol Assoc Lib. 2018 Jun 15; 215162:PF724. [cited 2019 Dec 5]. Available from: https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/215162\/alessandro.rambaldi.improved.survival.following.oms721.treatment.of.html","journal-title":"Eur Hematol Assoc Lib"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.373"},{"key":"e_1_3_4_64_1","unstructured":"MorphoSys AG. MorphoSys AG reports second quarter 2019 financial results. 2019 Aug 6. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.morphosys.com\/media-investors\/media-center\/morphosys-ag-reports-second-quarter-2019-financial-results."},{"key":"e_1_3_4_65_1","unstructured":"MorphoSys AG. MorphoSys AG: primary endpoint met in real-world data study demonstrating clinical superiority of the combination of tafasitamab and lenalidomide compared to lenalidomide alone. 2019 Oct 29. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.morphosys.com\/media-investors\/media-center\/morphosys-ag-primary-endpoint-met-in-real-world-data-study."},{"key":"e_1_3_4_66_1","unstructured":"MorphoSys AG. Primary endpoint of L-MIND a combination study of tafasitamab (MOR208) and lenalidomide has been met confirming previously published activity. 2019 May 16. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.morphosys.com\/media-investors\/media-center\/morphosys-ag-primary-endpoint-of-l-mind-a-combination-study-of."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy285"},{"key":"e_1_3_4_68_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron reports third quarter 2019 financial and operating results. 2019 Nov 5. press release. [cited 2019 Dec 5]. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-reports-third-quarter-2019-financial-and-operating."},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"e_1_3_4_70_1","unstructured":"Y-mabs Therapeutics Inc. Y-mAbs initiates rolling submission of biologics license application to U.S. FDA for naxitamab for treatment of neuroblastoma. 2019 Nov 29. press release. [cited 2019 Dec 5]. Available from: http:\/\/ir.ymabs.com\/node\/7156\/pdf."},{"key":"e_1_3_4_71_1","unstructured":"Y-mabs Therapeutics Inc. Y-mAbs announces naxitamab update. 2019 Oct 25. press release. [cited 2019 Dec 5]. Available from: http:\/\/ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-announces-naxitamab-update."},{"key":"e_1_3_4_72_1","unstructured":"Y-mabs Therapeutics Inc. Y-mAbs announces second quarter 2019 financial results and recent corporate developments. 2019 Aug 14. press release. http:\/\/ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-announces-second-quarter-2019-financial-results-and."},{"key":"e_1_3_4_73_1","unstructured":"Eli Lilly and Company. Pfizer and Lilly announce top-line results from long-term phase 3 study of tanezumab in patients with osteoarthritis. 2019 Apr 18. press release. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/pfizer-and-lilly-announce-top-line-results-long-term-phase-3."},{"key":"e_1_3_4_74_1","unstructured":"Eli Lilly and Company. Lilly reports second-quarter 2019 financial results raises 2019 EPS guidance. 2019 Jul 30. press release. [cited 2019 Dec 5]. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-reports-second-quarter-2019-financial-results-raises-2019."},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.8044"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0"},{"key":"e_1_3_4_77_1","unstructured":"Biogen Inc. Eisai Co. Ltd. Biogen plans regulatory filing for aducanumab in Alzheimer\u2019s disease based on new analysis of larger dataset from phase 3 studies. 2019 Oct 22. press release. [cited 2019 Dec 5]. Available from: http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease."},{"key":"e_1_3_4_78_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron announces positive topline results from phase 3 trial of evinacumab in patients with severe inherited form of high cholesterol. 2019 Aug 14. press release. [cited 2019 Dec 5]. Available from: https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/regeneron-announces-positive-topline-results-phase-3-trial."},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00039"},{"key":"e_1_3_4_80_1","unstructured":"Roche. Pipeline summary as of July 25 2019 (slides 5 72 73). [cited 2019 Dec 5]. Available from: https:\/\/www.roche.com\/dam\/jcr:9fb4878c-e3a2-4fdc-80f6-62d435df7367\/en\/pharmahy19.pdf."},{"key":"e_1_3_4_81_1","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L Feagan BG Mansfield J Rubin DT Arulmani U Maciuca R Tyrrell H Thommes J Tole S. Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study. European Crohn\u2019s and Colitis Organization meeting OP011. 2017. [cited 2019 Dec 5]. Available from: https:\/\/www.ecco-ibd.eu\/publications\/congress-abstract-s\/abstracts-2017\/item\/op011-etrolizumab-treatment-leads-to-early-improvement-in-symptoms-and-inflammatory-biomarkers-in-anti-tnf-refractory-patients-in-the-open-label-induction-cohort-of-the-phase-3-hickory-study.html.","DOI":"10.1093\/ecco-jcc\/jjx002.010"},{"key":"e_1_3_4_82_1","unstructured":"Bioveractiv Inc. Bioverativ announces first patient dosed in phase 3 study of BIVV009 for treatment of cold agglutinin disease. 2018 Mar 6. press release. [cited 2019 Dec 5]. Available from:\u00a0https:\/\/www.sanofigenzyme.com\/en\/about-us\/newsroom\/Bioverativ\/2018\/2018-03-06-07-30-00."},{"key":"e_1_3_4_83_1","unstructured":"Sanofi. Sanofi delivered solid growth in Q2 2019. 2019 Jul 29. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2019\/2019-07-29-07-30-00."},{"key":"e_1_3_4_84_1","unstructured":"Sanofi. Pivotal data from phase 3 study of sutimlimab in cold agglutinin disease to be presented at ASH 2019 late-breaking session. 2019 Nov 21. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.sanofigenzyme.com\/en\/about-us\/newsroom\/2019\/2019-11-21-09-22-00."},{"key":"e_1_3_4_85_1","unstructured":"AstraZeneca PLC. Year-to-date and Q3 2019 results. 2019 Oct 24. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2019\/q3\/Year-to-date_and_Q3_2019_Results_announcement.pdf."},{"key":"e_1_3_4_86_1","unstructured":"AstraZeneca PLC. Anifrolumab phase III trial meets primary endpoint in systemic lupus erythematosus. 2019 Aug 29. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html."},{"key":"e_1_3_4_87_1","unstructured":"AstraZeneca PLC. Anifrolumab demonstrated superiority across multiple efficacy endpoints in patients with systemic lupus erythematosus in phase III TULIP 2 trial. 2019 Nov 11. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/anifrolumab-demonstrated-superiority-across-multiple-efficacy-endpoints-in-patients-with-systemic-lupus-erythematosus-in-phase-iii-tulip-2-trial.html."},{"key":"e_1_3_4_88_1","unstructured":"Provention Bio Inc. Provention Bio announces PRV-031 (Teplizumab) granted PRIME designation by the European medicines agency. Oct 24 2019 press release. [cited 2019 Dec 5]. Available from: http:\/\/investors.proventionbio.com\/2019-10-24-Provention-Bio-Announces-PRV-031-Teplizumab-Granted-PRIME-Designation-by-the-European-Medicines-Agency."},{"key":"e_1_3_4_89_1","unstructured":"Provention Bio Inc. Provention Bio reiterates regulatory strategy for PRV-031 and announces completion of follow-on financing. 2019 Sept 24. press release. [cited 2019 Dec 5]. Available from: http:\/\/investors.proventionbio.com\/2019-09-24-Provention-Bio-Reiterates-Regulatory-Strategy-for-PRV-031-and-Announces-Completion-of-Follow-on-Financing."},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226"},{"key":"e_1_3_4_91_1","unstructured":"GlaxoSmithKline plc. Third quarter 2019. 2019 Oct 30. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.gsk.com\/media\/5735\/q3-2019-results-announcement.pdf."},{"key":"e_1_3_4_92_1","unstructured":"Sesen Bio. Sesen bio reports third quarter 2019 financial results and update on regulatory activities related to vicinium. 2019 Nov 12. press release. [cited 2019 Dec 5]. Available from: https:\/\/ir.sesenbio.com\/news-releases\/news-release-details\/sesen-bio-reports-third-quarter-2019-financial-results-and."},{"key":"e_1_3_4_93_1","volume-title":"Global Congress on Bladder Cancer 2018","author":"Dickstein R","year":"2018","unstructured":"Dickstein R, Wu N, Cowan B, Dunshee C, Franks M, Wolk F, Belkoff L, Castellucci S, Holzbeierlein J, Kulkarni G, et al. VISTA, phase 3 trial of Vicinium, an EPCAM-targeted Pseudomonas exotoxin, in BCG-unresponsive non-muscle invasive bladder cancer. Global Congress on Bladder Cancer 2018; 2018 Sep 20 \u2013 21; Madrid, Spain. [cited 2019 Dec 5]. Available from: https:\/\/sesenbio.com\/wp-content\/uploads\/2019\/01\/BLADDR_Congress_2018_Posterl.pdf."},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3069"},{"key":"e_1_3_4_95_1","unstructured":"MacroGenics provides update on corporate progress and second quarter 2019 financial results. 2019 Jul 31. press release. [cited 2019 Dec 5]. Available from: http:\/\/ir.macrogenics.com\/news-releases\/news-release-details\/macrogenics-provides-update-corporate-progress-and-second-3."},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.1000"},{"key":"e_1_3_4_97_1","unstructured":"GlaxoSmithKline. Second quarter 2019 results. 2019 Jul 24. press release. [cited 2019 Dec 5]. Available from: https:\/\/www.gsk.com\/media\/5663\/q2-2019-results-announcement.pdf."},{"key":"e_1_3_4_98_1","unstructured":"GlaxoSmithKline. Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer. 2019 Mar 19. press release. [cited 2019 Dec 5]. Available from: https:\/\/us.gsk.com\/en-us\/media\/press-releases\/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer\/."},{"key":"e_1_3_4_99_1","unstructured":"Novartis. Q3 2019 results. investor presentation. 2019 Oct 22. p.20. [cited 2019 Dec 5]. Available from: https:\/\/www.novartis.com\/sites\/www.novartis.com\/files\/q3-2019-ir-presentation.pdf"},{"key":"e_1_3_4_100_1","volume-title":"2019 American Society of Clinical Oncology Annual Meeting","author":"Long GV","unstructured":"Long GV, Lebbe C, Atkinson V, Mandal\u00e0 M, Nathan PD, Arance Fernandez AM, Richtig E, Yamazaki N, Robert C, Schadendorf D, et al. The anti\u2013PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600\u2013mutant melanoma: updated efficacy and safety from parts 1 and 2 of COMBI-i. Abstract #9531. 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4; Chicago, [cited 2019 Dec 5]. Available from:\u00a0 IL.https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.15_suppl.9531."},{"key":"e_1_3_4_101_1","unstructured":"Y-mAbs Therapeutics Inc. United States securities and exchange commission form 8-K. 2019 Nov 1. [cited 2019 Dec 5]. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1722964\/000110465919058623\/a19-21369_38k.htm."},{"key":"e_1_3_4_102_1","unstructured":"ADC Therapeutics SA. United States securities and exchange commission form F-1. 2019 Sept 6. [cited 2019 Dec 5]. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1771910\/000114036119016305\/nt10002526x5_f1.htm."},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2013.09.003"},{"key":"e_1_3_4_104_1","unstructured":"Agenus Inc. United States securities and exchange commission form 10-Q for the quarterly period ended June 30 2019. 2019 Aug 9. [cited 2019 Dec 5]. Available from: https:\/\/investor.agenusbio.com\/SEC-Filings."},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1133"},{"key":"e_1_3_4_106_1","unstructured":"AbbVie Inc. AbbVie discontinues rovalpituzumab tesirine (Rova-T) research and development program. 2019 Aug 29. press release. [cited 2019 Dec 5]. Available from: https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm."},{"key":"e_1_3_4_107_1","unstructured":"Eli Lilly and Company. Lilly to establish an access program for patients as it prepares to withdraw Lartruvo from the global market. 2019 Apr 25. press release. [cited 2019 Dec 5]. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-establish-access-program-patients-it-prepares-withdraw."}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2019.1703531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:01:52Z","timestamp":1762430512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2019.1703531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1080\/19420862.2019.1703531"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2019.1703531","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1703531"}}